The largest database of trusted experimental protocols

I8898

Manufactured by Merck Group
Sourced in United States

The I8898 is a laboratory equipment product manufactured by Merck Group. It serves as a versatile and precise tool for various scientific applications. The core function of the I8898 is to provide accurate measurements and data collection capabilities required in research and analytical settings. However, a detailed description while maintaining an unbiased and factual approach is not available at this time.

Automatically generated - may contain errors

4 protocols using i8898

1

Autophagy Modulation in COPD Pathogenesis

Check if the same lab product or an alternative is used in the 5 most similar protocols
HSAECs of normal and COPD were stimulated with 50 ​μg/mL lipopolysaccharide (LPS; L2630, Sigma, St. Louis, MO, USA) for 24 ​h after seeding into well-plate. Autophagy inhibitors were screened with a high-content imaging system. The experimental concentrations for analyzing the subsequent autophagy reaction, LC3B expression in the nucleus and cytoplasm, and small airway cell differentiation were 10 ​μM for CQ (1825–100, Biovision, Milpitas, CA, USA), 200 ​μM for IVM (I8898, Sigma), and 200 ​μM for 3-methyladenine (3-MA, tlrl-3ma, InvivoGen, San Diego, CA, USA).
+ Open protocol
+ Expand
2

Anthelmintic Efficacy Evaluation in Haemonchus

Check if the same lab product or an alternative is used in the 5 most similar protocols
Haemonchus contortus eggs were incubated for 24 h to obtain L1. Solutions consisting of 1 mL of L1 (~250 larvae) and 1 mL of treatment solution diluted with 3% Tween 80 and distilled water were incubated with GIN-free sheep feces for 6 days at room temperature (27 °C) [21 (link)]. LEV concentrations (T1512—Sigma-Aldrich®) ranged from 0.08 to 0.005 mg/mL, IVM concentrations (I8898—Sigma-Aldrich®) ranged from 0.05 to 0.0003 mg/mL, and CA from 2 at 0.125 mg/mL. The combination CA/LEV was evaluated at concentrations of 0.014 mg/mL LEV + 0.383 mg/mL AC to 8 × 10−4 mg/mL LEV + 0.023 mg/mL AC; for the combination CA/IVM, the concentrations were from 8.4 × 10−4 mg/mL IVM + 0.383 mg/mL CA to 5 × 10−5 mg/mL IVM + 0.023 mg/mL CA. In the negative control, 3% Tween 80 was used. L3 were retrieved according to the technique described by [22 (link)] and counted under the microscope. Three replicates were performed with five repetitions for each treatment and the control.
+ Open protocol
+ Expand
3

Quantitative Electropharyngogram Assay of Anthelmintics

Check if the same lab product or an alternative is used in the 5 most similar protocols
All EPG recordings were made in M9 buffer (Stiernagle, 2006 ), to which drugs, solvents or bacteria were added. Stocks of 5-Hydroxytryptamine creatinine sulfate complex (5HT, Sigma-Aldrich H7752; St. Louis, MO) were prepared in M9 at 40 mM, stored at −20 °C and diluted to desired concentrations in M9. Chip perfusion was initiated within 70 min of preparing a 5HT solution. Ivermectin (IVM; Sigma-Aldrich I8898) stocks (5 mM) were prepared in 100% DMSO and stored at −20 °C. The highest concentrations of DMSO that did not perturb EPG activity in control experiments were 0.2% (Fisher D-136) or 0.5% (Sigma-Aldrich Hybri-Max D2650) (data not shown) so these were the highest concentrations used in working solutions. Levamisole hydrochloride (LEV; Sigma 31,742) stocks (100 mM) were prepared in dH20 and stored at 4 °C until dilution on the day of use. Piperazine hexahydrate (PPZ; Sigma P7003) stocks (1M) were prepared in dH20 and stored at 4 °C until use. The pH of PPZ solutions was adjusted to 7.0 using HEPES buffer in M9 and titrating with 12 N HCl. Working solutions of all anthelmintic drugs were prepared from stocks and used on the same day. In some initial experiments, 0.005% Fast Green (Fisher F-99) was added to solutions to confirm uninterrupted perfusate flow (Lockery et al., 2012 (link)).
+ Open protocol
+ Expand
4

Preparation and Dilution of Antiviral Drugs

Check if the same lab product or an alternative is used in the 5 most similar protocols
All drugs were prepared to 10 mM stock solutions in 100% DMSO (Sigma) for niclosamide (N3510, Sigma) and ivermectin (I8898, Sigma), or water for chloroquine (HY-17589, MCE) and stored at − 80 °C. The drugs were diluted to the working concentrations in 2%FBS-MEM or 2%FBS-DMEM/F12 for the experiments in Vero E6 or Calu-3 cells, respectively. The final concentration of DMSO was 0.5% in all experiments.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!